We learned from Novo Nordisk that the European Commission has approved its marketing license for use in adult type 2 diabetics who are treated with basic insulin or GLP-1 receptor agonists but have poor blood sugar control, as an aid to diet and exercise, in combination with oral hypoglycemic agents. According to reports, Kyinsu is the world's first approved combination of the basic insulin weekly preparation Ecoinsulin and the GLP-1RA weekly preparation simeglutide. It is injected once a week.

We learned from Novo Nordisk that the European Commission has approved its marketing license for use in adult type 2 diabetics who are treated with basic insulin or GLP-1 receptor agonists but have poor blood sugar control, as an aid to diet and exercise, in combination with oral hypoglycemic agents. According to reports, Kyinsu is the world's first approved combination of the basic insulin weekly preparation Ecoinsulin and the GLP-1RA weekly preparation simeglutide. It is injected once a week.